Download University of Pennsylvania Abramson Cancer Center clinical trials

University of Pennsylvania Abramson Cancer Center clinical trials for patients with pancreatic cancer
Highlights June 26, 2014
Treatment
Chemotherapy plus Vitamin D
analogue
Chemotherapy plus
hydoxychloroquine
Chemotherapy plus Jak-1 inhibitor
Engineered T cell therapy
(mesothelin)
PARP inhibitor
Gemcitabine chemotherapy vs.
FOLFIRINOX chemotherapy
CD40 antibody with chemotherapy
Radiation plus chemotherapy
Combination vaccine with or without
checkpoint blockade
Tumor antigen vaccine
Radiation plus checkpoint blockade
Eligible patients
Patients undergoing primary
surgical resection
Patients with metastatic
cancer
Patients with metastatic
cancer
Patients with advanced
metastatic cancer
Patients with BRCA1 or BRCA2
mutations and advanced
metastatic disease
Patients after primary surgical
resection
Patients with resectable
disease
Patients with borderline
resectable disease, or
unresectable (but not
metastatic) disease
Patients with metastatic
disease
Patients in remission after
surgery and adjuvant therapy
Patients with metastatic
disease
*Funded by one of two grants to Penn from Stand Up to Cancer
Status
Open at Penn*
Open at Penn
Open at Penn and nationally
Active but not recruiting
Open at Penn and
internationally
Open at Penn
Preclinical studies complete.
Initial trial complete. Next trial
to open later this winter at
Penn*
Open next month at Penn
To open later this fall at Penn*
To open later this fall at Penn
Preclinical studies complete;
trial design in progress